OPKO Health takes over Silcon
The acquisition is expected to expand OPKO’s business in Chile and Mexico in addition to obtaining permission for commercialization of OPKO 4KScore prostate cancer test in Brazil. OPKO
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The approval was based on positive data from liver transplant study that compared Zortress in combination with reduced-exposure tacrolimus to standard tacrolimus. Zortress, which is cleared for use